Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2Other solid neoplasm 1Gastrointestinal 1Dermatologic 1

Conditions

Neoplasms 2Neoplasm Metastasis 1

Interventions

Paclitaxel 27Carboplatin 25pembrolizumab 22Gemcitabine 22Nivolumab 21Cisplatin 15Docetaxel 14Bevacizumab 14Pemetrexed 12Ipilimumab 12Erlotinib Hydrochloride 12Capecitabine 12Irinotecan 11Fluorouracil 11Afatinib 10eribulin 9BI 6727 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9Radiotherapy 8Magnetic Resonance Spectroscopy 8Leucovorin 8Everolimus 8Cyclophosphamide 8olaparib 7Oxaliplatin 7lenvatinib 6avelumab 6Trastuzumab 6Cetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × LY3022855 × Tumor-Agnostic × Clear all
NCT02265536 2024-10-28

A Study of LY3022855 In Participants With Breast or Prostate Cancer

Eli Lilly and Company

Phase 1 Completed
34 enrolled 17 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01346358 2024-09-19

A Study of IMC-CS4 in Subjects With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
52 enrolled 23 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡